KTTAW
Pasithea Therapeutics Corp.
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 100 |
Stock Information
| Cash Equivalents | $50.40M |
| Net Income | $-19.73M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-19.73M |
| Book/sh | $2.20 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 33.84 |
| Current Ratio | 35.40 |
Returns & Margins
| ROA | -31.49% |
| ROE | -58.22% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| RSI | nan |
| Shares Float | 18.68M |
| Volatility | 0.25 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | +6.86% |
| 10 Years | +6.86% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.01 | 0 |
| 2026-06-17 | $0.01 | 0 |
| 2026-06-16 | $0.01 | 0 |
| 2026-06-15 | $0.01 | 0 |
| 2026-06-12 | $0.01 | 0 |
| 2026-06-11 | $0.01 | 0 |
| 2026-06-10 | $0.01 | 0 |
| 2026-06-09 | $0.01 | 0 |
| 2026-06-08 | $0.01 | 0 |
| 2026-06-05 | $0.01 | 0 |
| 2026-06-04 | $0.01 | 0 |
| 2026-06-03 | $0.01 | 0 |
| 2026-06-02 | $0.01 | 0 |
| 2026-06-01 | $0.01 | 0 |
| 2026-05-29 | $0.01 | 0 |
| 2026-05-28 | $0.01 | 0 |
| 2026-05-27 | $0.01 | 0 |
| 2026-05-26 | $0.01 | 0 |
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | $113,195 |
| Cost Of Revenue | - | - | - | $113,195 |
| Expenses | ||||
| Total Expenses | $20,857,295 | $14,249,962 | $15,979,361 | $12,588,971 |
| Other Income Expense | $102,419 | $-77,806 | $56,245 | $861,086 |
| Other Non Operating Income Expenses | $380,532 | - | - | $10,633 |
| Net Non Operating Interest Income Expense | $327,193 | $423,184 | $415,368 | $0 |
| Operating Expense | $20,857,295 | $14,249,962 | $15,979,361 | $12,588,971 |
| General And Administrative Expense | $12,876,175 | $7,051,468 | $7,878,596 | $9,923,544 |
| Interest Expense | - | - | - | $102 |
| Interest Expense Non Operating | - | - | - | $102 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-20,427,683 | $-13,904,584 | $-15,507,748 | $-11,727,885 |
| Net Interest Income | $327,193 | $423,184 | $415,368 | $0 |
| Interest Income | $327,193 | $423,184 | $415,368 | $0 |
| Normalized Income | $-20,153,742 | $-13,826,778 | $-15,563,993 | $-12,578,338 |
| Net Income From Continuing And Discontinued Operation | $-20,427,683 | $-13,904,584 | $-15,961,658 | $-13,936,452 |
| Total Operating Income As Reported | $-20,857,295 | $-14,249,962 | $-15,979,361 | $-12,588,971 |
| Net Income Common Stockholders | $-20,427,683 | $-13,904,584 | $-15,961,658 | $-13,936,452 |
| Net Income | $-20,427,683 | $-13,904,584 | $-15,961,658 | $-13,936,452 |
| Net Income Including Noncontrolling Interests | $-20,427,683 | $-13,904,584 | $-15,961,658 | $-13,936,452 |
| Net Income Continuous Operations | $-20,427,683 | $-13,904,584 | $-15,507,748 | $-11,727,885 |
| Pretax Income | $-20,427,683 | $-13,904,584 | $-15,507,748 | $-11,727,885 |
| Interest Income Non Operating | $327,193 | $423,184 | $415,368 | $0 |
| Operating Income | $-20,857,295 | $-14,249,962 | $-15,979,361 | $-12,588,971 |
| Net Income Discontinuous Operations | - | $0 | $-453,910 | $-2,208,567 |
| Special Income Charges | - | - | $0 | $-1,001,736 |
| Gross Profit | - | - | - | $373,364 |
| Other | ||||
| Tax Effect Of Unusual Items | $-4,172 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-19,916,597 | $-13,523,127 | $-15,387,152 | $-13,434,330 |
| Total Unusual Items | $-278,113 | $-77,806 | $56,245 | $850,453 |
| Total Unusual Items Excluding Goodwill | $-278,113 | $-77,806 | $56,245 | $850,453 |
| Reconciled Depreciation | $662,585 | $649,029 | $648,454 | $5,094 |
| EBITDA (Bullshit earnings) | $-20,194,710 | $-13,600,933 | $-15,330,907 | $-12,583,877 |
| EBIT | $-20,857,295 | $-14,249,962 | $-15,979,361 | $-12,588,971 |
| Diluted NI Availto Com Stockholders | $-20,427,683 | $-13,904,584 | $-15,961,658 | $-13,936,452 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-278,113 | $-77,806 | $56,245 | $1,852,189 |
| Research And Development | $7,981,120 | $7,198,494 | $8,100,765 | $2,665,427 |
| Selling General And Administration | $12,876,175 | $7,051,468 | $7,878,596 | $9,923,544 |
| Other Gand A | $12,876,175 | $7,051,468 | $7,878,596 | $9,923,544 |
| Other Special Charges | - | - | - | $1,001,736 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $51,438,252 | $6,208,615 | $14,194,227 | $32,663,859 |
| Total Assets | $60,240,070 | $16,064,719 | $26,116,858 | $45,180,089 |
| Total Non Current Assets | $3,780,986 | $8,696,404 | $9,424,704 | $11,103,396 |
| Goodwill And Other Intangible Assets | $3,780,986 | $8,574,061 | $9,204,225 | $9,834,389 |
| Other Intangible Assets | $3,780,986 | $7,311,150 | $7,941,314 | $8,571,478 |
| Current Assets | $56,459,084 | $7,368,315 | $16,692,154 | $34,076,693 |
| Other Current Assets | $387,823 | $142,945 | $104,707 | $262,992 |
| Restricted Cash | $100,866 | $0 | - | - |
| Prepaid Assets | $811,456 | $302,641 | $215,895 | $562,375 |
| Cash Cash Equivalents And Short Term Investments | $55,158,939 | $6,922,729 | $16,331,052 | $33,087,864 |
| Cash And Cash Equivalents | $55,158,939 | $6,922,729 | $16,331,052 | $33,087,864 |
| Cash Equivalents | $53,400,000 | $6,100,000 | $13,400,000 | - |
| Cash Financial | $1,758,939 | $822,729 | $2,931,052 | $33,146,895 |
| Receivables | - | $0 | $40,500 | $0 |
| Assets Held For Sale Current | - | - | $0 | $163,462 |
| Other Receivables | - | - | $40,500 | $302,132 |
| Other Non Current Assets | - | - | - | $643,382 |
| Debt | ||||
| Total Debt | - | $0 | $81,680 | $504,383 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $344,021 |
| Current Debt And Capital Lease Obligation | - | - | $81,680 | $160,362 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,020,832 | $1,282,043 | $2,718,406 | $2,681,841 |
| Total Non Current Liabilities Net Minority Interest | $46,871 | $162,172 | $84,366 | $804,207 |
| Derivative Product Liabilities | $46,871 | $162,172 | $84,366 | $140,611 |
| Current Liabilities | $4,973,961 | $1,119,871 | $2,634,040 | $1,877,634 |
| Other Current Liabilities | $3,842,857 | - | - | $235,879 |
| Payables And Accrued Expenses | $1,131,104 | $1,119,871 | $2,552,360 | $1,481,393 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $319,575 |
| Equity | ||||
| Common Stock Equity | $55,219,238 | $14,782,676 | $23,398,452 | $42,498,248 |
| Total Equity Gross Minority Interest | $55,219,238 | $14,782,676 | $23,398,452 | $42,498,248 |
| Stockholders Equity | $55,219,238 | $14,782,676 | $23,398,452 | $42,498,248 |
| Gains Losses Not Affecting Retained Earnings | $18,766 | $-7,171 | $-4,652 | $-661 |
| Other Equity Adjustments | $18,766 | $-7,171 | $-4,652 | $-661 |
| Retained Earnings | $-70,010,461 | $-49,582,778 | $-35,318,538 | $-19,356,880 |
| Other | ||||
| Ordinary Shares Number | $23,091,062 | $1,394,263 | $1,041,582 | $1,302,170 |
| Share Issued | $23,091,062 | $1,394,263 | $1,041,582 | $1,302,170 |
| Tangible Book Value | $51,438,252 | $6,208,615 | $14,194,227 | $32,663,859 |
| Invested Capital | $55,219,238 | $14,782,676 | $23,398,452 | $42,498,248 |
| Working Capital | $51,485,123 | $6,248,444 | $14,058,114 | $32,199,059 |
| Total Capitalization | $55,219,238 | $14,782,676 | $23,398,452 | $42,498,248 |
| Additional Paid In Capital | $125,208,624 | $64,372,486 | $58,721,538 | $61,855,659 |
| Capital Stock | $2,309 | $139 | $104 | $130 |
| Common Stock | $2,309 | $139 | $104 | $130 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $1,262,911 | $1,262,911 | $1,262,911 |
| Net PPE | $0 | $122,343 | $220,479 | $625,625 |
| Accumulated Depreciation | $0 | $-42,353 | $-23,488 | $-3,559 |
| Gross PPE | $0 | $164,696 | $243,967 | $629,184 |
| Leases | $0 | $3,193 | $3,193 | $3,193 |
| Machinery Furniture Equipment | $0 | $6,140 | $6,140 | $26,343 |
| Properties | $0 | $0 | $0 | $0 |
| Capital Lease Obligations | - | $0 | $81,680 | $504,383 |
| Current Capital Lease Obligation | - | $0 | $81,680 | $160,362 |
| Other Properties | - | $155,363 | $234,634 | $599,648 |
| Long Term Capital Lease Obligation | - | - | $0 | $344,021 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,211,490 | $-13,923,438 | $-13,459,712 | $-13,798,259 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,211,490 | $-13,923,438 | $-13,425,411 | $-13,691,158 |
| Cash Flow From Continuing Operating Activities | $-15,211,490 | $-13,923,438 | $-12,814,133 | $-11,894,567 |
| Operating Gains Losses | $411,811 | $77,806 | $-121,293 | $-1,852,189 |
| Cash From Discontinued Operating Activities | - | $0 | $-611,278 | $-1,796,591 |
| Investing Activities | ||||
| Investing Cash Flow | $11,000 | $0 | $399,006 | $-2,926,597 |
| Cash Flow From Continuing Investing Activities | $11,000 | $0 | $75,199 | $-2,299,699 |
| Cash From Discontinued Investing Activities | - | $0 | $323,807 | $-626,898 |
| Capital Expenditure | - | - | $-34,301 | $-107,101 |
| Net Other Investing Changes | - | - | $109,500 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $61,717,208 | $0 | - | $0 |
| Financing Cash Flow | $63,518,800 | $4,517,634 | $-3,726,416 | $-3,206,244 |
| Cash Flow From Continuing Financing Activities | $63,518,800 | $4,517,634 | $-3,726,416 | $-3,206,244 |
| Net Other Financing Charges | $-448,279 | $-481,499 | - | - |
| Net Common Stock Issuance | $61,717,208 | $0 | $-3,726,416 | $-3,206,244 |
| Common Stock Issuance | $61,717,208 | $0 | - | $0 |
| Repurchase Of Capital Stock | - | $0 | $-3,726,416 | $-3,206,244 |
| Cash From Discontinued Financing Activities | - | $0 | $0 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $13,212 | $0 | - | - |
| Income Tax Paid Supplemental Data | $0 | $0 | - | - |
| End Cash Position | $55,259,805 | $6,922,729 | $16,331,052 | $33,087,864 |
| Beginning Cash Position | $6,922,729 | $16,331,052 | $33,087,864 | $52,901,962 |
| Effect Of Exchange Rate Changes | $18,766 | $-2,519 | $-3,991 | $9,900 |
| Changes In Cash | $48,318,310 | $-9,405,804 | $-16,752,821 | $-19,823,998 |
| Proceeds From Stock Option Exercised | $2,249,871 | $4,517,634 | $0 | $0 |
| Net PPE Purchase And Sale | $11,000 | $0 | $-34,301 | $-107,101 |
| Sale Of PPE | $11,000 | $0 | - | - |
| Change In Working Capital | $-318,581 | $-1,519,382 | $1,574,185 | $845,349 |
| Change In Other Current Liabilities | $0 | $-2,409 | $-1,547 | $543,956 |
| Change In Other Current Assets | $-269,278 | $2,262 | $158,285 | $-262,992 |
| Change In Payables And Accrued Expense | $11,233 | $-1,432,489 | $1,070,967 | $745,759 |
| Change In Prepaid Assets | $-60,536 | $-86,746 | $346,480 | $-181,374 |
| Stock Based Compensation | $297,467 | $773,693 | $592,269 | $835,064 |
| Asset Impairment Charge | $4,162,911 | $0 | - | $423,412 |
| Depreciation Amortization Depletion | $662,585 | $649,029 | $648,454 | $5,094 |
| Depreciation And Amortization | $662,585 | $649,029 | $648,454 | $5,094 |
| Amortization Cash Flow | $630,164 | $630,164 | $630,164 | $0 |
| Amortization Of Intangibles | $630,164 | $630,164 | $630,164 | $0 |
| Depreciation | $32,421 | $18,865 | $18,290 | $5,094 |
| Gain Loss On Investment Securities | $301,318 | $77,806 | $-56,245 | $-1,852,189 |
| Net Foreign Currency Exchange Gain Loss | $7,171 | $0 | - | - |
| Net Income From Continuing Operations | $-20,427,683 | $-13,904,584 | $-15,507,748 | $-11,727,885 |
| Repayment Of Debt | - | $0 | $-392,354 | $0 |
| Issuance Of Debt | - | $0 | $392,354 | $0 |
| Common Stock Payments | - | $0 | $-3,726,416 | $-3,206,244 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $0 |
| Net Long Term Debt Issuance | - | $0 | $0 | $0 |
| Long Term Debt Payments | - | $0 | $-392,354 | $0 |
| Long Term Debt Issuance | - | $0 | $392,354 | $0 |
| Purchase Of PPE | - | $0 | $-34,301 | $-107,101 |
| Net Business Purchase And Sale | - | - | $0 | $-2,192,598 |
| Purchase Of Business | - | - | $0 | $-2,192,598 |
| Sale Of Business | - | - | - | $77,060 |
| Net Intangibles Purchase And Sale | - | - | - | $-1,763,717 |
| Purchase Of Intangibles | - | - | - | $-1,763,717 |
| Other Non Cash Items | - | - | - | $356,550 |
Fetched: 2026-06-24